コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 lycerides and a 12% reduction in low-density lipoprotein cholesterol.
2 ratios of triglycerides to very low-density lipoprotein cholesterol.
3 olipoproteins A-I and B, or very low-density lipoprotein cholesterol.
4 th hypertriglyceridemia and low high-density lipoprotein cholesterol.
5 lycerides, and 95.0% (19/20) for low-density lipoprotein cholesterol.
6 nd triglyceride, and increasing high-density lipoprotein cholesterol.
7 te as large as that of total or high-density lipoprotein cholesterol.
8 r risk as on-treatment levels of low-density lipoprotein cholesterol.
9 45- to 64-year-old men with high low-density lipoprotein cholesterol.
10 lower adult weight and total and low-density lipoprotein cholesterol.
11 the effect of statin on lowering low-density lipoprotein cholesterol.
12 es potent statin therapy and low low-density lipoprotein cholesterol.
13 to hypertriglyceridemia and low high-density lipoprotein cholesterol.
14 ially improve triglycerides and high-density lipoprotein cholesterol.
15 ressure, total cholesterol, and high-density lipoprotein cholesterol.
16 ssure, albuminuria, smoking, and low-density lipoprotein cholesterol.
17 al, HR-corrected QT interval or high-density lipoprotein-cholesterol.
18 inverse association of FT4 with low-density lipoprotein-cholesterol.
19 , but was associated with lower high density lipoprotein cholesterol (-0.014 standard deviation, 95%
20 roup had greater improvements in low-density lipoprotein cholesterol (-0.2 mmol/l; p < 0.001), systol
21 [1.1-2.1]), and borderline low high-density lipoprotein cholesterol (1.4 [1.0-1.8]) remained signifi
22 holesterol (1.6 [1.2-2.2]), high low-density lipoprotein cholesterol (1.6 [1.1-2.1]), and borderline
23 (3.7 [2.0-7.0]), borderline high low-density lipoprotein cholesterol (1.6 [1.2-2.2]), high low-densit
24 holesterol (27.9 to 60.0%), non-high-density lipoprotein cholesterol (10.0 to 36.6%), apolipoprotein
25 mg/dL (178.17-191.31 mg/dL); for low-density lipoprotein cholesterol, 109.23 mg/dL (103.68-114.79 mg/
26 val, 18-27; P<1.0x10(-4)), lower low-density lipoprotein cholesterol (-12.2 mg/dL; 95% confidence int
27 y significantly increased serum high-density lipoprotein cholesterol (13 trials; net change: 3.2 mg/d
28 ty lipoprotein cholesterol), 8 (high-density lipoprotein cholesterol), 14 (triglycerides), and 19 (to
29 d versus risk based) with higher low-density lipoprotein cholesterol (140 versus133 mg/dL; P=0.01).
30 cholesterol (1.3 to 32.9%), very-low-density lipoprotein cholesterol (27.9 to 60.0%), non-high-densit
31 g/dL (103.68-114.79 mg/dL); for high-density lipoprotein cholesterol, 42.80 mg/dL (39.84-45.76 mg/dL)
32 ter acute coronary syndrome with low-density lipoprotein cholesterol 50 to 125 mg/dL were randomized
33 gle-nucleotide polymorphisms for low-density lipoprotein cholesterol, 71 single-nucleotide polymorphi
34 nce were found on chromosomes 7 (low-density lipoprotein cholesterol), 8 (high-density lipoprotein ch
35 total cholesterol, -8 mg/dl for low-density lipoprotein cholesterol, +8 mg/dl for remnant cholestero
36 ted with unsaturated fats lowers low-density lipoprotein cholesterol, a cause of atherosclerosis, lin
37 /kexin type 9), markedly reduces low-density lipoprotein cholesterol across diverse patient populatio
38 tic peptide, and lower levels of low-density lipoprotein cholesterol, adiponectin, lipoprotein-associ
39 were observed with achieved non-high-density lipoprotein cholesterol and apolipoprotein B100 levels o
41 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the
42 or blood lipids, such as for the low-density lipoprotein cholesterol and coronary artery disease risk
43 ificant variants associated with low-density lipoprotein cholesterol and coronary heart disease at AP
44 els, women had higher levels of high-density lipoprotein cholesterol and high-density lipoprotein par
45 inment, exercise, levels of non-high-density lipoprotein cholesterol and high-sensitivity C-reactive
47 was positively associated with high-density-lipoprotein cholesterol and intakes of polyunsaturated f
48 mass index, active smoking, and low-density lipoprotein cholesterol and lipoprotein(a) levels were i
49 ationship between lower achieved low-density lipoprotein cholesterol and lower risk of limb events (P
50 tudy) randomized men with raised low-density lipoprotein cholesterol and no history of myocardial inf
51 Lipid Clinic criteria, including low-density lipoprotein cholesterol and personal and family history
52 g new target for lowering plasma low-density lipoprotein cholesterol and preventing cardiovascular di
54 esterol, and ratios of total to high-density lipoprotein cholesterol and triglycerides to high-densit
55 de, can effectively lower plasma low-density lipoprotein-cholesterol and apolipoprotein B levels, but
57 ers (B) (NT-proBNP, hs-cTnT, and low-density lipoprotein cholesterol), and clinical variables (C) (sm
58 le-nucleotide polymorphisms for high-density lipoprotein cholesterol, and 40 single-nucleotide polymo
59 p between additional LDL-C, non-high-density lipoprotein cholesterol, and apolipoprotein B100 reducti
61 including glycated hemoglobin, high-density lipoprotein cholesterol, and C-reactive protein, did not
63 ts and had higher triglycerides, low-density lipoprotein cholesterol, and HbA1c and lower high-densit
64 ties (high fasting glucose, low high-density lipoprotein cholesterol, and high triglyceride levels an
65 us, high-density lipoprotein and low-density lipoprotein cholesterol, and IHD to create GRSs for each
66 ty lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and ratios of total to high-den
67 sm, educational attainment, and high-density lipoprotein cholesterol, and significant negative geneti
68 density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglyceride levels were me
69 density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides for further s
71 traits (total, low-density and high-density lipoprotein cholesterol, and triglycerides) are risk fac
73 in cholesterol; lower levels of high-density lipoprotein cholesterol; and, to a lesser extent, elevat
74 erved in total cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprote
76 tive exposure to lower levels of low-density lipoprotein cholesterol are not associated with neurocog
77 nly childhood lipid measures for low-density lipoprotein cholesterol (area under the receiver-operati
78 acebo in individuals with normal low-density lipoprotein cholesterol but increased C-reactive protein
79 inhibitors substantially reduce low-density lipoprotein cholesterol, but it is presently unclear whe
81 long exposure to lower levels of low-density lipoprotein cholesterol can provide information on the p
83 wer median time-weighted average low-density lipoprotein cholesterol compared with placebo/simvastati
84 index, apolipoprotein A-1, and high-density lipoprotein cholesterol concentration (beta -0.22; P = 0
85 lood glucose concentration, low high-density lipoprotein cholesterol concentration, hypertension, and
86 condary analyses conditioning on low-density lipoprotein cholesterol concentration, the epsilon2 prot
87 , including variants involved in low-density lipoprotein cholesterol concentrations, schizophrenia, a
88 ss index, heart rate, total and high-density lipoprotein cholesterol concentrations, smoking, and the
89 scular disease (CVD) context and low density lipoprotein-cholesterol concentrations within a saturate
90 scores for BMI, HDL cholesterol, low-density lipoprotein cholesterol, coronary artery disease, C-reac
91 , respectively; both p < 0.001), low-density lipoprotein cholesterol (correlation coefficient 0.30 an
92 ferential responses in total and low-density lipoprotein cholesterol (decreased in LFHC group only),
93 ognitive impairment per 20 mg/dL low-density lipoprotein cholesterol decrements were 1.02 (95% CI, 0.
94 or various covariates including high-density lipoprotein cholesterol, each 1 unit of natural logarith
95 riers of PTV at CETP had higher high-density lipoprotein cholesterol (effect size, 22.6 mg/dL; 95% co
97 of fasting total cholesterol to high-density lipoprotein cholesterol, estimated glomerular filtration
98 kers (diastolic blood pressure, high-density lipoprotein cholesterol, fasting and 2-hour glucose, fas
99 triglyceride, total cholesterol, low-density lipoprotein cholesterol, fasting glucose, diabetes melli
101 ted to phenotypic FH, defined by low-density lipoprotein cholesterol >/=190 mg/dL, is likely substant
104 with HeFH (age, 6-<18 years) and low-density lipoprotein cholesterol >4.9 mmol/L or >4.1 mmol/L in co
105 ighest versus lowest quartile of low-density lipoprotein cholesterol (>/= 146 versus </= 102 mg/dL) w
106 olesterol (TC) (>/= 200 mg/dL), high-density lipoprotein cholesterol (HDL-C) (<40 mg/dL), and non-HDL
107 the inverse association between high-density lipoprotein cholesterol (HDL-C) and risk of cardiovascul
108 ase (CAD), but the relevance of high-density lipoprotein cholesterol (HDL-C) and triglycerides (TGs)
109 The prognostic importance of high-density lipoprotein cholesterol (HDL-C) as a specific risk facto
110 miologic studies, higher plasma high-density lipoprotein cholesterol (HDL-C) has been associated with
111 emic stroke, and a low level of high-density lipoprotein cholesterol (HDL-C) is also considered to be
112 protein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were either directly mea
114 cluding total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein
115 Levels of serum cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein
116 ed with total cholesterol (TC), high-density-lipoprotein cholesterol (HDL-C), low-density-lipoprotein
119 sociated with triglycerides and high-density lipoprotein cholesterol (HDL-C; cg27243685; P=8.1E-26 an
120 ipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], and triglycerides), APO
121 fractions (triglycerides [TGs], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein
122 etabolic outcomes, estimates for low-density lipoprotein cholesterol, HDL cholesterol, triglycerides,
124 significantly higher levels of high density lipoprotein cholesterol (HDLc) were observed in individu
125 ration, systolic blood pressure, low-density lipoprotein cholesterol, hemoglobin A1c, albuminuria, gl
126 ty, elevated triglycerides, low high-density lipoprotein cholesterol, high blood pressure, and elevat
127 iovascular disease risk factors: low-density lipoprotein cholesterol, high-density lipoprotein choles
129 ing levels of total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-choles
130 dication use increased at higher low-density lipoprotein cholesterol in ARIC but not in REGARDS or KP
132 e recently approved for lowering low-density lipoprotein cholesterol in heterozygous familial hyperch
133 hite blood cell count and lower high-density lipoprotein cholesterol in men, and with higher BMI and
134 e of lower levels of circulating low-density lipoprotein cholesterol in mice lacking miR-146a in BM-d
137 reased in LFHC group only), and high-density lipoprotein cholesterol (increased in VHFLC group only).
139 ients with primary elevations of low-density lipoprotein cholesterol (LDL-C) >/=190 mg/dL are at a hi
140 fferent PCSK9 GOF mutations with low-density lipoprotein cholesterol (LDL-C) >/=70 mg/dL on their cur
141 l, total cholesterol <240 mg/dl, low-density lipoprotein cholesterol (LDL-C) <160 mg/dl, and high-den
143 udies, and whether low levels of low-density lipoprotein cholesterol (LDL-C) alter this association i
144 by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) and accelerated atherosc
145 tions of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (ap
146 espread use of statins to reduce low-density lipoprotein cholesterol (LDL-C) and associated atheroscl
147 zed by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) and extremely high risk
149 lationship between reductions in low-density lipoprotein cholesterol (LDL-C) and major adverse cardio
150 a CVD risk factor when levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) a
152 gs (n = 1071, 6-104 weeks) found low-density lipoprotein cholesterol (LDL-C) decreases of 20% to 40%;
154 viduals with increased levels of low-density lipoprotein cholesterol (LDL-C) have shown modest result
157 elevated 10-year risk (>5%) or a low-density lipoprotein cholesterol (LDL-C) level of 4.92 mmol/L (19
158 d targeting or using a threshold low-density lipoprotein cholesterol (LDL-C) level of less than 70 mg
159 adult patients with uncontrolled low-density lipoprotein cholesterol (LDL-C) levels and history of in
160 ibody against PCSK9 that reduces low-density lipoprotein cholesterol (LDL-C) levels by 55% to 75%.
161 ients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels despite use of st
162 harmful consequences of elevated low-density lipoprotein cholesterol (LDL-C) levels in young adults m
163 protein (CETP) inhibitors lower low-density lipoprotein cholesterol (LDL-C) levels without reducing
164 cus are strongly associated with low-density lipoprotein cholesterol (LDL-C) levels, as well as with
167 the effects of lifetime reduced low-density lipoprotein cholesterol (LDL-C) on cardiovascular events
168 in the context of low levels of low-density lipoprotein cholesterol (LDL-C) or non-high-density lipo
169 hat intraindividual variation in low-density lipoprotein cholesterol (LDL-C) predicts both cerebrovas
172 monoclonal antibodies can reduce low-density lipoprotein cholesterol (LDL-C) to very low levels when
173 t to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH pa
175 hether the relative reduction in low-density lipoprotein cholesterol (LDL-c) was a good indicator of
176 Importance: Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive statin th
177 lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG).
178 lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides were
179 lipoprotein cholesterol (HDL-C), low-density-lipoprotein cholesterol (LDL-C), and/or triglycerides (T
180 evated total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C), is associated with dysl
181 evated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is frequently seen in o
184 y International Trial, intensive low-density lipoprotein cholesterol (LDL-C)-reducing therapy with ez
189 e was a significant reduction in low density lipoprotein-cholesterol (LDL-C), an increase in CEC and
190 ls of total cholesterol (T-CHL), low density lipoprotein-cholesterol (LDL-CHL), and resistin were hig
191 ant cholesterol (80% relative to low-density lipoprotein cholesterol [LDL-C]), but only modest loweri
192 ipid markers (total cholesterol, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotei
193 lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], total cholesterol [TC])
195 ype was associated with elevated low density lipoprotein cholesterol (LDLc) and total cholesterol (TC
196 iglyceride level <100 mg/dL, and low-density lipoprotein cholesterol level <100 mg/dL (n = 158).
197 -0.16]; 23 trials [n = 58022]), low-density lipoprotein cholesterol level (-2.58 mg/dL [95% CI, -4.3
198 de level (-40%, -29%, and -8%), high-density lipoprotein cholesterol level (32%, 30%, and 7%), use of
199 s, we stratified participants by low-density lipoprotein cholesterol level at index ages from 20 to 7
202 mg/dL or a final screening non-high-density lipoprotein cholesterol level of at least 100 mg/dL.
205 ivity, total cholesterol level, high-density lipoprotein cholesterol level, systolic blood pressure,
209 known ASCVD, diabetes mellitus, low-density lipoprotein cholesterol levels <70 or >/=190 mg/dl, prio
210 ion) in the cohort with elevated low-density lipoprotein cholesterol levels (ie, >/=190 mg/dL), 52.4%
211 dies led to marked reductions in low-density lipoprotein cholesterol levels (mean difference, -47.49%
212 reductions in blood pressure and low-density lipoprotein cholesterol levels and improvements in measu
213 39 (T39(-/-)) display increased high-density lipoprotein cholesterol levels associated with increased
214 vels greater than 204 mg/dL and high-density lipoprotein cholesterol levels less than 34 mg/dL (HR, 0
215 otic cardiovascular disease with low-density lipoprotein cholesterol levels of at least 70 mg/dL (to
216 price of $10311 in patients with low-density lipoprotein cholesterol levels of at least 80 mg/dL.
217 ndividuals with elevated fasting low-density lipoprotein cholesterol levels were also randomized to p
220 ore likely to smoke, have lower high-density lipoprotein cholesterol levels, and have higher predicte
221 evated triglyceride levels, low high-density lipoprotein cholesterol levels, high blood pressure, and
222 ow-density lipoprotein, and non-high-density lipoprotein cholesterol levels, in triglyceride levels,
225 ensity lipoprotein cholesterol, high-density lipoprotein cholesterol, lipoprotein(a), triglycerides,
226 olesterol, and -8 mg/dl for non-high-density lipoprotein cholesterol; lipoprotein(a), apolipoprotein
228 analysis for total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholest
229 lysis that were associated with high-density lipoprotein cholesterol, low-density lipoprotein cholest
230 of PTV at CETP displayed higher high-density lipoprotein cholesterol, lower low-density lipoprotein c
231 y lipoprotein cholesterol, lower low-density lipoprotein cholesterol, lower triglycerides, and lower
232 ow-density lipoprotein, and non-high-density lipoprotein cholesterol; lower levels of high-density li
233 tended follow-up of statin-based low-density lipoprotein cholesterol lowering trials improves the und
235 the highlights of the history of low-density lipoprotein-cholesterol lowering, with the discovery of
240 ters-aspirin use, lipid control (low-density lipoprotein cholesterol <70 mg/dL or statin therapy), bl
242 interval (CI): 0.2, 4.6), higher low-density lipoprotein cholesterol (MD = 1.3 mg/dL, 95% CI: 0.1, 2.
244 (LDL-C), triglycerides, and non-high-density lipoprotein cholesterol (non-HDL-C) presented similar in
248 ntial long-term effects of lower low-density lipoprotein cholesterol on neurocognitive impairment and
249 h weight was not associated with low density lipoprotein cholesterol or triglycerides, but was associ
250 ths had the highest odds of low high-density lipoprotein cholesterol (OR, 1.5; 95% confidence interva
251 und for fasting plasma glucose, high-density lipoprotein cholesterol, or triglycerides within both gr
252 ensity lipoprotein-cholesterol, high-density lipoprotein-cholesterol, or triglyceride, 4 weighted GRS
253 scavenger receptors for oxidized low-density lipoprotein cholesterol (ox-LDL), plays a crucial role i
256 able analysis, older age, higher low-density lipoprotein cholesterol, pack per year of smoking, and h
257 biochemical (e.g., carotenoids, high-density lipoprotein cholesterol), physiological (e.g., upper leg
258 .31 +/- 0.10 mmol/L; P = 0.024), low-density lipoprotein cholesterol (PY = -0.35 +/- 0.10 mmol/L, LF
259 ained by lowering of non-HDL-C (high-density lipoprotein cholesterol), rather than increases in HDL-C
260 lic phenotypes, including total:high-density lipoprotein cholesterol ratio (rG=-0.44, P=0.005), high-
261 n use, and total cholesterol to high-density lipoprotein cholesterol ratio were associated with CVEs.
262 itiation of statin treatment for low-density lipoprotein cholesterol reduction in children with HeFH.
263 on quantitative trait loci for a low-density lipoprotein cholesterol-related differentially methylate
264 the tails of the white and black low-density lipoprotein cholesterol response distributions, whereas
265 lates LDLR and may contribute to low-density lipoprotein cholesterol response to statin treatment.
266 schooling (rG=0.18, s.e.=0.03), high-density lipoprotein cholesterol (rG=0.28, s.e.=0.05), smoking (r
268 ets for systolic blood pressure, low-density lipoprotein cholesterol, smoking, physical activity, and
270 st circumference, triglyceride, high-density lipoprotein cholesterol, systolic and diastolic blood pr
271 ion, hemoglobin A1c testing, and low-density lipoprotein cholesterol testing), prescribing appropriat
272 ion, hemoglobin A1c testing, and low-density lipoprotein cholesterol testing), prescribing appropriat
273 its estimated from reductions in low-density lipoprotein cholesterol that occurred in PCSK9i trials w
274 ivity and a 35% increase of the high density lipoprotein cholesterol that was observed up to 32 days
275 Low-fat diets tend to improve low-density lipoprotein cholesterol the most, while lower-carbohydra
277 istory, more stringent age-based low-density lipoprotein cholesterol thresholds, or alternative lipid
278 is found to be associated with high-density lipoprotein cholesterol through gene-based association a
279 gh-density lipoprotein [HDL] and low-density lipoprotein-cholesterol, total cholesterol, and triglyce
280 c Cardiovascular Risk in Adults, low-density lipoprotein cholesterol treatment thresholds have been r
282 of SCOPA to two GWAS of high-and low-density lipoprotein cholesterol, triglycerides and body mass ind
283 tervention in rats reduced serum low-density lipoprotein cholesterol, triglycerides and triglyceride-
284 Reductions in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and fasting gluc
285 lood sample (total cholesterol, high-density lipoprotein cholesterol, triglycerides, glucose, fasting
286 plasma glucose, glycohemoglobin, low-density lipoprotein cholesterol, triglycerides, high-sensitivity
287 ensity lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, type 2 diabetes
288 ith changes of fasting glucose, high-density lipoprotein-cholesterol, triglycerides, systolic blood p
289 /V(p)=31.4%, P<3.1x10(-11)) and high-density lipoprotein cholesterol (V(G)/V(p)=26.4%, P<4.2x10(-12))
290 ve biomarkers (concentration of high-density lipoprotein cholesterol, vitamin D and C-reactive protei
296 ions in mean levels of total and low-density lipoprotein cholesterol were greater after distal gastri
297 ntervention, and higher level of low-density lipoprotein cholesterol were independent predictors of e
298 ardiac troponin T (hs-cTnT), and low-density lipoprotein cholesterol, where NT-proBNP and hs-cTnT had
299 stolic blood pressure and lower high-density lipoprotein cholesterol with Carotid artery intima-media
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。